Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
08:00am, Monday, 05'th May 2025
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will
Novel engineering approach to developing an mRNA-encoded masked IL-12 therapeutic demonstrates potent anti-tumor activity with significantly enhanced tolerability Novel engineering approach to develop
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
11:15am, Friday, 25'th Apr 2025
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Tuesday, 11'th Mar 2025
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
06:35pm, Thursday, 06'th Mar 2025
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to earnings of $0.01 per share a year a
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
06:34pm, Thursday, 06'th Mar 2025
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants R
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
04:10pm, Thursday, 06'th Mar 2025
- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 -
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
08:00am, Wednesday, 05'th Mar 2025
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
10:45am, Tuesday, 04'th Mar 2025
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
08:00am, Thursday, 27'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
01:16pm, Tuesday, 07'th Jan 2025
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
04:05pm, Monday, 06'th Jan 2025
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipat
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:57am, Monday, 16'th Dec 2024
CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
08:00am, Wednesday, 27'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean M
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
10:35am, Tuesday, 19'th Nov 2024
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
